- Home
- SLDB vs KALV Comparison
SLDB vs KALV Comparison
Compare SLDB & KALV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SLDB
- KALV
- Stock Information
- Founded
- SLDB 2013
- KALV N/A
- Country
- SLDB United States
- KALV United States
- Employees
- SLDB N/A
- KALV N/A
- Industry
- SLDB Biotechnology: Biological Products (No Diagnostic Substances)
- KALV Biotechnology: Pharmaceutical Preparations
- Sector
- SLDB Health Care
- KALV Health Care
- Exchange
- SLDB Nasdaq
- KALV Nasdaq
- Market Cap
- SLDB 464.1M
- KALV 551.2M
- IPO Year
- SLDB 2018
- KALV N/A
- Fundamental
- Price
- SLDB $4.52
- KALV $13.88
- Analyst Decision
- SLDB Strong Buy
- KALV Strong Buy
- Analyst Count
- SLDB 10
- KALV 8
- Target Price
- SLDB $14.70
- KALV $26.43
- AVG Volume (30 Days)
- SLDB 1.3M
- KALV 1.4M
- Earning Date
- SLDB 11-03-2025
- KALV 11-10-2025
- Dividend Yield
- SLDB N/A
- KALV N/A
- EPS Growth
- SLDB N/A
- KALV N/A
- EPS
- SLDB N/A
- KALV N/A
- Revenue
- SLDB N/A
- KALV $1,426,000.00
- Revenue This Year
- SLDB N/A
- KALV N/A
- Revenue Next Year
- SLDB N/A
- KALV $234.65
- P/E Ratio
- SLDB N/A
- KALV N/A
- Revenue Growth
- SLDB N/A
- KALV N/A
- 52 Week Low
- SLDB $2.41
- KALV $7.30
- 52 Week High
- SLDB $7.37
- KALV $17.28
- Technical
- Relative Strength Index (RSI)
- SLDB 42.74
- KALV 64.53
- Support Level
- SLDB $4.16
- KALV $10.55
- Resistance Level
- SLDB $4.73
- KALV $14.97
- Average True Range (ATR)
- SLDB 0.45
- KALV 0.80
- MACD
- SLDB 0.01
- KALV 0.41
- Stochastic Oscillator
- SLDB 40.63
- KALV 75.22
About SLDB Solid Biosciences Inc.
Solid Biosciences Inc is a life science company. It is engaged in the manufacturing of specialty and generic drugs. The company is involved in curing Duchenne muscular dystrophy (DMD), a genetic muscle-wasting disease predominantly affecting boys, with symptoms that usually manifest between three and five years of age. The company's pipeline products are the SB-001 and solid suit. The Company's singular focus is on developing treatments through gene therapy and other means for patients with neuromuscular and cardiac diseases. The company has categorized its programs into corrective therapies, disease-modifying therapies, and assistive devices.
About KALV KalVista Pharmaceuticals Inc.
KalVista Pharmaceuticals Inc is a pharmaceutical company developing and delivering oral therapies for individuals affected by rare diseases with unmet needs. The company applies its knowledge in the kallikrein-kinin system (KKS) and oral drug discovery to develop small-molecule protease inhibitor medicines to address the needs of patients with diseases driven by plasma kallikrein and Factor XIIa. Its FDA-approved product EKTERLY (sebetralstat) is a novel, orally delivered, small-molecule plasma kallikrein inhibitor for the treatment of acute attacks of hereditary angioedema (HAE) in adult and pediatric patients aged twelve years and older.